Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TaiGen On-Track for 2014 China Approval of Novel Antibiotic

publication date: May 1, 2014
TaiGen Biotech of Taiwan said that the CFDA review of Taigexyn®, a novel antibiotic for community-acquired pneumonia, is proceeding smoothly. The company is discussing price with China authorities, according to Ming-chu Hsu, CEO and chairman of TaiGen. Two years ago, TaiGen out-licensed China rights for Taigexyn to Zhejiang Medicine. TaiGen anticipates the antibiotic will generate $1.6 million of revenues in China, once it receives final marketing approval later this year. More details....

Stock Symbol: (TWO: 4157)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital